TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on June 22 regarding positive topline results of a phase III clinical study, in prurigo nodularis (OLYMPIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.
Please refer to the link below for details of the press release:
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab
Chugai Pharmaceutical Co., Ltd.
Media Relations Group
Corporate Communications Dept.
(C) 2022 Electronic News Publishing, source ENP Newswire